Novartis Trims Its Sails, Divests Blood-Testing Unit To Spain’s Grifols
CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.
CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.